Compare DexCom, Inc. (DXCM) vs NIO Inc. (NIO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs NIO Inc. — how do they compare? DexCom, Inc. trades at $90.29 (market cap $33.79B), while NIO Inc. trades at $4.57 (market cap $11.59B). The key difference: DexCom, Inc. is far larger — about 2.9× NIO Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, NIO Inc. nearer its low. Which is the better fit depends on your goals.
| DXCM | NIO | |
|---|---|---|
Market Cap | $33.79B | $11.59B |
Sector | Health | Consumer Cyclical |
52-Week High | $89.53 | $7.89 |
52-Week Low | $54.84 | $4.44 |
Enterprise Value | $33.24B | $10.82B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $87.65, up 3.42% today and near its 52-week high, with a bullish technical signal from moving averages and strong fundamental performance. Revenue grew to $4.66B in 2025, with net income reaching $836.30M and a 20.12% net margin. Recent Q2 2026 earnings beat expectations with $0.70 EPS, and the company raised full-year guidance, reflecting robust demand for its continuous glucose monitoring systems.
The outlook remains positive given consistent earnings beats, margin expansion, and analyst consensus favoring a buy rating with a $88.65 price target. Key risks include competitive pressures in medical devices and potential regulatory scrutiny, but growth drivers like G7 adoption and international expansion support upside potential for investors.
NIO's stock trades at $4.575, down 5.08% amid bearish technical signals and negative cash flows. Revenue grew to $87.49 billion in 2025, but net losses persist at -$15.57 billion. Recent news highlights delivery growth and competitive pressures in China's EV market, with shares near support levels after a steep decline from 2026 highs.
The outlook remains challenged by profitability concerns and high debt, though analyst consensus leans bullish with 54% buy ratings. Key risks include intense competition and reliance on financing, while potential upside hinges on margin improvement and sustained delivery growth in a volatile sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About NIO Inc.
NIO Inc. manufactures and sells automobiles. The Company offers electric vehicles and parts, as well as provides battery charging services. NIO serves customers worldwide.
Read more on NIO →
